Drug Search Results
More Filters [+]

Gaboxadol

Alternative Names: gaboxadol, ov-101, ov101, ov 101
Latest Update: 2024-05-10
Latest Update Note: PubMed Publication

Product Description

Gaboxadol (OV101) is a delta-subunit–selective, extrasynaptic GABAA receptor agonist that enhances GABAergic tonic inhibition, providing the rationale for assessment of OV101 as a potential targeted treatment of FXS. No drug is approved in the United States for the treatment of FXS. (Sourced from: https://www.frontiersin.org/articles/10.3389/fphar.2021.757825/full#:~:text=Gaboxadol%20(OV101)%20is%20a%20%CE%B4,for%20the%20treatment%20of%20FXS.)

Mechanisms of Action: GABA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ovid
Company Location: NEW YORK NY 10036
Company CEO: Jeremy M. Levin
Additonal Commercial Interests: Healx

Clinical Description

Map of Global Clinical Trials for Gaboxadol

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Angelman Syndrome

Phase 2: Fragile X Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT06334419

P2

Recruiting

Fragile X Syndrome

2024-09-30

ELARA

P3

Completed

Angelman Syndrome

2021-06-04

Recent News Events